Glucagon-like peptide-1 receptor agonists (GLP1-RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) were recently introduced as novel classes of drugs for treating patients with type 2 diabetes (T2D). This evidence concerns the gene GCG and type 2 diabetes mellitus.